In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria

Autores
Imperiale, Belen Rocio; Mancino, María Belén; Moyano, Roberto Damian; de la Barrera, Silvia; Morcillo, Nora
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Antimicrobial resistance is a global health problem. In 2021, it was estimated almost half a million of multidrug-resistant tuberculosis (MDR-TB) cases. Besides, non-tuberculous mycobacteria (NTM) are highly resistant to several drugs and the emergence of fluoroquinolone (FQ) resistant M. tuberculosis (Mtb) is also a global concern making treatments difficult and with variable outcome. The aim of this study was to evaluate the activity of the FQ, DC-159a, against Mtb and NTM and to explore the cross-resistance with the currently used FQs. A total of 12 pre-extensively drug-resistant (XDR) Mtb, 2 XDR, 36 fully drug susceptible strains and 41 NTM isolates were included to estimate the in vitro activity of DC-159a, moxifloxacin (MOX) and levofloxacin (LX), using minimal inhibitory and bactericidal concentration (MIC and MBC). The activity inside the human macrophages and pulmonary epithelial cells were also determined. DC-159a was active in vitro and ex vivo against mycobacteria. Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX. DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases.
Instituto de Biotecnología
Fil: Imperiale, Belen Rocio. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); Argentina
Fil: Imperiale, Belen Rocio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mancino, María Belén. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; Argentina
Fil: Moyano, Roberto Damian. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Moyano, Roberto Damian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: de la Barrera, Silvia. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); Argentina
Fil: de la Barrera, Silvia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Morcillo, Nora. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; Argentina
Fuente
The Journal of Antibiotics 77 (5) : 306-314 (May 2024)
Materia
Antibiotics
Tuberculosis
Mycobacterium
Antimicrobial Resistance
Antibiótico
Resistencia a los Antimicrobianos
Nivel de accesibilidad
acceso restringido
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/18738
Acceder
id INTADig_2eb1cee5a3f7137c60e9a9c5545fd346
oai_identifier_str oai:localhost:20.500.12123/18738
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteriaImperiale, Belen RocioMancino, María BelénMoyano, Roberto Damiande la Barrera, SilviaMorcillo, NoraAntibioticsTuberculosisMycobacteriumAntimicrobial ResistanceAntibióticoResistencia a los AntimicrobianosAntimicrobial resistance is a global health problem. In 2021, it was estimated almost half a million of multidrug-resistant tuberculosis (MDR-TB) cases. Besides, non-tuberculous mycobacteria (NTM) are highly resistant to several drugs and the emergence of fluoroquinolone (FQ) resistant M. tuberculosis (Mtb) is also a global concern making treatments difficult and with variable outcome. The aim of this study was to evaluate the activity of the FQ, DC-159a, against Mtb and NTM and to explore the cross-resistance with the currently used FQs. A total of 12 pre-extensively drug-resistant (XDR) Mtb, 2 XDR, 36 fully drug susceptible strains and 41 NTM isolates were included to estimate the in vitro activity of DC-159a, moxifloxacin (MOX) and levofloxacin (LX), using minimal inhibitory and bactericidal concentration (MIC and MBC). The activity inside the human macrophages and pulmonary epithelial cells were also determined. DC-159a was active in vitro and ex vivo against mycobacteria. Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX. DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases.Instituto de BiotecnologíaFil: Imperiale, Belen Rocio. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); ArgentinaFil: Imperiale, Belen Rocio. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Mancino, María Belén. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; ArgentinaFil: Moyano, Roberto Damian. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Moyano, Roberto Damian. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: de la Barrera, Silvia. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); ArgentinaFil: de la Barrera, Silvia. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Morcillo, Nora. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; ArgentinaJapan Antibiotics Research Association2024-08-01T10:06:25Z2024-08-01T10:06:25Z2024-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/18738https://www.nature.com/articles/s41429-024-00709-31881-1469https://doi.org/10.1038/s41429-024-00709-3The Journal of Antibiotics 77 (5) : 306-314 (May 2024)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/restrictedAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-11-06T09:42:12Zoai:localhost:20.500.12123/18738instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-11-06 09:42:12.762INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
title In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
spellingShingle In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
Imperiale, Belen Rocio
Antibiotics
Tuberculosis
Mycobacterium
Antimicrobial Resistance
Antibiótico
Resistencia a los Antimicrobianos
title_short In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
title_full In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
title_fullStr In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
title_full_unstemmed In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
title_sort In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
dc.creator.none.fl_str_mv Imperiale, Belen Rocio
Mancino, María Belén
Moyano, Roberto Damian
de la Barrera, Silvia
Morcillo, Nora
author Imperiale, Belen Rocio
author_facet Imperiale, Belen Rocio
Mancino, María Belén
Moyano, Roberto Damian
de la Barrera, Silvia
Morcillo, Nora
author_role author
author2 Mancino, María Belén
Moyano, Roberto Damian
de la Barrera, Silvia
Morcillo, Nora
author2_role author
author
author
author
dc.subject.none.fl_str_mv Antibiotics
Tuberculosis
Mycobacterium
Antimicrobial Resistance
Antibiótico
Resistencia a los Antimicrobianos
topic Antibiotics
Tuberculosis
Mycobacterium
Antimicrobial Resistance
Antibiótico
Resistencia a los Antimicrobianos
dc.description.none.fl_txt_mv Antimicrobial resistance is a global health problem. In 2021, it was estimated almost half a million of multidrug-resistant tuberculosis (MDR-TB) cases. Besides, non-tuberculous mycobacteria (NTM) are highly resistant to several drugs and the emergence of fluoroquinolone (FQ) resistant M. tuberculosis (Mtb) is also a global concern making treatments difficult and with variable outcome. The aim of this study was to evaluate the activity of the FQ, DC-159a, against Mtb and NTM and to explore the cross-resistance with the currently used FQs. A total of 12 pre-extensively drug-resistant (XDR) Mtb, 2 XDR, 36 fully drug susceptible strains and 41 NTM isolates were included to estimate the in vitro activity of DC-159a, moxifloxacin (MOX) and levofloxacin (LX), using minimal inhibitory and bactericidal concentration (MIC and MBC). The activity inside the human macrophages and pulmonary epithelial cells were also determined. DC-159a was active in vitro and ex vivo against mycobacteria. Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX. DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases.
Instituto de Biotecnología
Fil: Imperiale, Belen Rocio. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); Argentina
Fil: Imperiale, Belen Rocio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mancino, María Belén. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; Argentina
Fil: Moyano, Roberto Damian. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Moyano, Roberto Damian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: de la Barrera, Silvia. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); Argentina
Fil: de la Barrera, Silvia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Morcillo, Nora. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; Argentina
description Antimicrobial resistance is a global health problem. In 2021, it was estimated almost half a million of multidrug-resistant tuberculosis (MDR-TB) cases. Besides, non-tuberculous mycobacteria (NTM) are highly resistant to several drugs and the emergence of fluoroquinolone (FQ) resistant M. tuberculosis (Mtb) is also a global concern making treatments difficult and with variable outcome. The aim of this study was to evaluate the activity of the FQ, DC-159a, against Mtb and NTM and to explore the cross-resistance with the currently used FQs. A total of 12 pre-extensively drug-resistant (XDR) Mtb, 2 XDR, 36 fully drug susceptible strains and 41 NTM isolates were included to estimate the in vitro activity of DC-159a, moxifloxacin (MOX) and levofloxacin (LX), using minimal inhibitory and bactericidal concentration (MIC and MBC). The activity inside the human macrophages and pulmonary epithelial cells were also determined. DC-159a was active in vitro and ex vivo against mycobacteria. Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX. DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases.
publishDate 2024
dc.date.none.fl_str_mv 2024-08-01T10:06:25Z
2024-08-01T10:06:25Z
2024-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/18738
https://www.nature.com/articles/s41429-024-00709-3
1881-1469
https://doi.org/10.1038/s41429-024-00709-3
url http://hdl.handle.net/20.500.12123/18738
https://www.nature.com/articles/s41429-024-00709-3
https://doi.org/10.1038/s41429-024-00709-3
identifier_str_mv 1881-1469
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/restrictedAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv restrictedAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Japan Antibiotics Research Association
publisher.none.fl_str_mv Japan Antibiotics Research Association
dc.source.none.fl_str_mv The Journal of Antibiotics 77 (5) : 306-314 (May 2024)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1848045981840441344
score 13.142177

Publicaciones similares